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Short report
Successful clozapine re-challenge in a
patient with three previous episodes of
clozapine-associated blood dyscrasia
Jessica Foster*, John Lally*, Victoria Bell and Sukhi Shergill
A case is presented of a 30-year-old female with
treatment-resistant schizoaffective disorder who was
referred to a tertiary-level specialist psychosis service.
We describe the history of clozapine trials and associated
episodes of agranulocytosis and neutropenia, followed by
the successfully tolerated third clozapine re-challenge
within our service.
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Resistance to antipsychotic treatment is defined as failure to
respond to two antipsychotics of adequate dose and duration1 and
occurs in 30% of individuals with schizophrenia.2 Clozapine is the
only medication with evidence-based effectiveness in treatment-
resistant schizophrenia,1 being effective in 50–60% of cases,3 but is
also associated with a broad range of adverse effects. A commonly
accepted risk is clozapine-induced blood dyscrasia, typically
neutropenia or agranulocytosis. Neutropenia is defined as a
neutrophil count of less than 1.5×109/L, occurring at a rate of
2.7% of clozapine users at 1 year.4 Patients who develop
neutropenia may develop flu-like symptoms such as sore throat
and pyrexia, with the peak risk occurring at 6–18 weeks. Less
common is agranulocytosis, a life-threatening event defined as a
neutrophil count of less than 0.5×109/L, occurring in approxi-
mately 0.8% of clozapine users at 1 year.4
Dispensing of clozapine is dependent on a satisfactory full
blood count (FBC) result and maintenance of normal white blood
cell (WBC) and neutrophil counts during clozapine treatment.
In established clozapine-induced neutropenia or agranulocytosis,
clozapine is immediately discontinued, and given the increased
risk of recurrence,5 re-challenge is contraindicated. However, re-
challenge may be attempted under certain conditions, for example,
due to an alternative cause of the reduced neutrophil count
being identified, or after careful assessment of the clinical risks
and benefits. This process involves collaboration with a haematologist
and may involve the co-administration of lithium or granulocyte
colony stimulating factor (GCS-F) in an attempt to promote
granulocyte proliferation and increase the WBC and neutrophil
counts. Despite carefully controlled re-challenge, a third of patients
will develop a further blood dyscrasia, which is often more rapid in
onset and more severe.5
In this report, we add to the limited existing evidence of
successfully re-challenging clozapine for a third time with a patient
with treatment-resistant schizoaffective disorder, following two
episodes of agranulocytosis and one of episode of neutropenia.
Case report
J.B. is a 30-year-old Caucasian woman with a diagnosis of
schizoaffective disorder. She was born and raised abroad before
moving to the UK at the age of 21 years. J.B. first presented with
psychotic symptoms at the age of 19 years. Over the next decade, she
had multiple admissions to psychiatric hospitals, both informally
and under Section 3 of the Mental Health Act. Her illness
was characterised by mixed affective episodes associated with per‐
secutory delusions, thought disorder and auditory hallucinations,
often triggered by stress or periods of non-adherence to medication.
During admission to our service, persecutory beliefs were about
other patients, staff and visitors, and led to accusations of theft
of her belongings, accusations of sexual assault and physical aggression.
Periodically, she became suspicious about the side-effects of
medications and declined to adhere to their administration. There
was a significant labile component to her mood, fluctuating between
laughing and verbal or physical aggression. Between episodes, J.B.
was pleasant, engaged in recovery-oriented practices and appeared
less preoccupied and distressed by positive psychotic symptoms.
During the first 7 years of her illness, J.B. was treated with
multiple antipsychotics (i.e. quetiapine, aripiprazole, risperidone,
olanzapine, amisulpride, haloperidol, sulpiride, zuclopenthixol
decanoate and flupentixol decanoate), mood stabilisers (lithium
carbonate and sodium valproate) and a course of electroconvulsive
therapy (ECT) with minimal improvement documented in case
notes. Given the treatment-resistant nature of her illness, clozapine
was commenced.
J.B. had no significant past medical history and was not taking
any medication for her physical health. Routine admission bloods
including an autoimmune screen, hepatitis screen and liver function
tests were all within normal ranges. J.B. smoked continually during
all clozapine titrations, and the phenomenon of altered clozapine
metabolism with smoking has been documented6; we monitored
clozapine serum levels and dosage adjustments were made.
Clozapine treatments
Table 1 provides a summary of clozapine trials and recorded
measures.
Trial 1
J.B. was first commenced on clozapine in July 2011. At this time, she
was also receiving quetiapine and sodium valproate. Pre-treatment
FBC showed a WBC count of 5.8×109/L and a neutrophil count of
2.9×109/L. WBC and neutrophil counts remained within normal
limits until week 17, when J.B. developed agranulocytosis with
a nadir WBC count of 2.0×109/L and a neutrophil count of*These authors contributed equally to the work.
BJPsych Open (2017)
3, 22–25. doi: 10.1192/bjpo.bp.116.003467
22
0.41×109/L. The daily dose of clozapine was 300 mg, with a plasma
clozapine concentration of 0.17 mg/dL. Clozapine was immediately
stopped and olanzapine was commenced as an alternative. The
blood dyscrasia persisted for 19 days in total before cell counts
recovered. Case records from the previous hospital indicated a
significant improvement in her clinical state with clozapine, and
discontinuation was associated with a rapid increase in her
psychotic symptoms.
Trial 2
A second clozapine challenge was initiated in February 2012.
Sodium valproate was discontinued prior to the second clozapine
trial. At this time, J.B. was concurrently treated with olanzapine
10 mg and lithium carbonate 300 mg daily. An FBC prior to re-
challenge with clozapine showed a WBC count of 8.0×109/L and a
neutrophil count of 4.4×109/L. Six weeks after re-commencement of
clozapine, J.B. developed a neutropenia, with a nadir neutrophil
count of 0.53×109/L and a WBC of 1.9×109/L. Clozapine was
immediately discontinued following consultationwith a haematologist.
The neutrophil count normalised over the next 20 days, during
which time she was treated with an increased dose of olanzapine
15 mg and sulpiride 200 mg daily.
Trial 3
In September 2012, after a careful risk–benefit assessment and
in collaboration with a haematologist, a third clozapine trial was
commenced. On this occasion, J.B. was being treated with topira‐
mate 400 mg and amisulpride 400 mg daily. She was commenced
on weekly subcutaneous injections of GCS-F, with 480 mcg of
filgrastim. After 18 weeks of treatment, she developed agranulocy-
tosis with neutrophils dropping to 0.40×109/L and a WBC count of
2.6×109/L. By this time, clozapine had been titrated to 400 mg daily.
Following consultation with a haematologist, J.B. continued cloza-
pine treatment with an additional dose of filgrastim 480mcg given
that day. This resulted in a good response, with the neutrophil count
increasing to 19.2×109/L and theWBC to 23.10×109/L the following
day. A plan was formulated to increase the frequency of filgrastim
injections to twice weekly in the event of further neutropenia;
however, this was not required. J.B. was maintained on clozapine,
with weekly filgrastim for a further 7 months, and was discharged
to a rehabilitation service. However, she subsequently became
non-adherent with clozapine.
Trial 4
Following admission to our service in October 2013, a range of
pharmacotherapeutic interventions were attempted, including zuclo-
penthixol decanoate, quetiapine, olanzapine, amisulpride and lithium,
all with minimal beneficial effect. In October 2014, following specialist
consultations, the multidisciplinary team agreed collaboratively with
the patient and family to re-challenge with clozapine for a third time
under close supervision. She was deemed to have capacity to be part of
each of these decisions. Following consultation with a haematologist
and pharmacist, lithium carbonate was commenced prior to
clozapine initiation, and weekly FBCs were measured over the
first year of clozapine treatment. It was planned that in the event
of the neutrophil count dropping below 2×109/L, a single dose of
105 mcg of lenograstim was to be administered subcutaneously, and
clozapine was to be continued with daily blood monitoring. In the
event of the neutrophil count dropping below 1.5×109/L, a single
dose of 105 mcg lenograstim was to be administered, and clozapine
treatment immediately terminated. Lenograstim was to be used in
preference to filgrastim because of increased experience with its use
in our clinical setting.
Pre-treatment FBC demonstrated a WBC count of 8.43×109/L
and a neutrophil count of 5.7×109/L. Standard clozapine titration
was carried out as per Maudsley Guidelines,7 and clozapine was
increased to a dose of 550 mg daily administered in liquid form.
Lithium carbonate at 1200 mg daily was concurrently used, with
serum lithium levels of 0.55–0.95 mmol/L attained. Weekly FBCs
across the first year demonstrated stable WBC and neutrophil
counts, with no episodes of neutropenia or the need for rescue
lenograstim. Consistently, therapeutic plasma clozapine concen-
trations of around 0.35–0.40 mg/L were attained, without further
haematological complications despite continuation of clozapine,
and a dramatic improvement in mental state was observed.
Discussion
Owing to the severity and distressing nature of this young woman’s
psychotic and mood symptoms and the lack of response to a
number of antipsychotic medications, clozapine was re-challenged
following specialist consultations and close monitoring practices.
The results were promising given the failure of three previous
attempts and thus support the need for measured re-challenging
and augmentation practices. In a recent systematic review, cloza-
pine re-challenge was successful in 70% (78/112 patients) after an
episode of neutropenia, with 20% (3/15 patients) successfully
re-challenged after agranulocytosis.8 The co-administration of
lithium (33/35 patients) or GCS-F (7/11 patients), in a targeted
strategy, decreased the likelihood of developing a further blood
dyscrasia.8 We reported previously that a clozapine re-challenge
was successful in 79% of patients (n=19) admitted to our service.9
The effective treatment of schizoaffective disorder often re‐
quires the use of several psychopharmacological agents,10 and
polypharmacy may have played a part in this case. The first trial
of clozapine was concurrent with the use of sodium valproate.
Sodium valproate can cause a dose-dependent inhibition of
granulopoiesis,11 which when combined with clozapine may have
led to the agranulocytosis. In the second trial, clozapine re-challenge
occurred in combination with lithium carbonate. Lithium carbonate
has demonstrated the ability to increase circulating neutrophils
and granulocyte colony formation.12–14 Although a neutropenia
Table 1 Summary of clozapine trials and recorded measures
Clozapine trial Start date Time until
neutropenia
Daily
clozapine dose
Clozapine level
(mg/dL)
Neutrophil
nadir
Time to
recovery
Other
medications
1 July 2011 17 weeks 300mg 0.17a 0.41b 19 days (spontaneous) Quetiapine
Valproate
2 Feb 2012 6 weeks Not available Not available 0.53 20 days (spontaneous) Lithium
Olanzapine
3 Sep 2012 18 weeks 400mg Not available 0.40 1 day (GCS-F) (and
clozapine trial continued
for a further 7 months)
Topiramate
Amisulpride
GCS-F
4 Oct 2014 Not available 550mg 0.35 Not available Not available Lithium
GCS-F, granulocyte colony stimulating factor.
a. Clozapine level: 0.17mg/dL is equivalent to 170 ng/mL.
b. Neutrophil nadir: 0.41×109/L is equivalent to 410/mm3 (cells).
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occurred during this trial, it is interesting to note that the neutrophil
count did not drop as low as seen in the first trial. During the
third trial, J.B. was treated with concurrent G-CSF, and although
agranulocytosis still occurred, neutrophil recovery was 1 day, which
was significantly shorter than the recovery seen in the first and
second trials. We are unable to explain this transient episode of
agranulocytosis and the lack of any recurrent neutropenia over the
following 7 months of clozapine treatment with concurrent G-CSF
(with no G-CSF dose change). We cannot exclude that a transient
increase in plasma clozapine concentrations was related to the
onset of agranulocytosis (we have no data relating to plasma
clozapine concentrations at that time, nor do we know if the patient
had ceased smoking at or around this time). Alternatively, the
presence of a viral infection may have contributed to the onset of
agranulocytosis, though this was not clinically documented.
During the fourth trial, lithium carbonate was used with
therapeutic serum levels attained. Previous work has suggested
that serum lithium levels greater than 0.4 mmol/L are required for
granulopoiesis.14 Given the low dose of lithium carbonate used
during the second trial, it may be that there were insufficient lithium
levels to promote granulocyte colony formation at that time and
that the optimal serum lithium levels in the fourth trial supported
the maintenance of normal neutrophil counts.
Despite neutropenia and agranulocytosis being well-documented
complications of clozapine treatment, the mechanism of action
remains unclear.15 There are several hypotheses, but due to its
idiosyncratic nature it has been difficult to perform mechanistic
studies to investigate these in a systematic fashion. Clozapine-
induced agranulocytosis (CIA) has a large genetic component;
genetic data suggest dysfunction in the human leucocyte antigen
(HLA) system, which comprises genes that modulate immune
system function. Recent work has suggested that there is an
association with several genetic variants in the HLA-DQB1 locus,
a single amino acid at HLA-DQB1 (126Q) and an amino acid
change in the extracellular binding pocket of HLA-B (158T).16
Both toxic and immune-mediated mechanisms have also been
suggested as being important in the aetiology of CIA. The prevailing
thinking is that many idiosyncratic drug reactions like CIA are
secondary to the formation of reactive metabolites. Clozapine has
been shown in vitro to be oxidised by themyeloperoxidase system to
reactive electrophilic nitrenium ions. This oxidation to bioactive
nitrenium occurs in the liver and peripheral neutrophils. These
bioactive metabolites are proposed to directly affect bone marrow
and circulating cells. The reactive nitrenium ions may bind to
neutrophils to cause cell death. They may trigger an immune
response in susceptible individuals leading to neutrophilic precur-
sors in the bone marrow being targeted (equivalent to what occurs
in a drug hypersensitivity reaction). It is possible that the target in
agranulocytosis could be stromal cells and neutrophil precursors in
the bone marrow,17 whereas the main target in neutropenia
may only be the peripheral blood neutrophils.18 Clozapine further
appears to accelerate the process of apoptosis through oxidative
mitochondrial stress, rendering the neutrophils highly susceptible
to oxidant-induced apoptosis. Apoptosis is induced in weeks 4–12
after starting clozapine, corresponding to the period when agranu-
locytosis is most likely to occur.19 The recurrence of CIA does not
usually occur very rapidly on re-challenge (i.e. within days), although
this should not be taken to be indicative of a non-immune-mediated
mechanism. In general, a subsequent neutropenic event on clozapine
re-challenge tends to occur earlier and is more severe, consistent
with an immune-mediated event.5 Further, a majority of patients
treated with clozapine exhibit evidence of a systemic inflammatory
response with raised cytokines, fever or paradoxical increases
in WBC seen in the earlier stages of treatment.20 Other potential
causes hypothesised as primary or contributory factors to
neutropenia associated with clozapine include benign ethnic
neutropenia (BEN), which may be present in up to a quarter of
individuals of African or Middle Eastern descent,21 and the
concurrent use of other drugs with potential to affect bone marrow
function.22
It is justifiable that there is widespread reluctance to instigate a
clozapine re-challenge following an episode of neutropenia or
agranulocytosis. We conclude that, in an appropriate environment
and under the care of a highly specialised expert multidisciplinary
team, it is appropriate to instigate a re-challenge with clozapine in
selected patients with treatment-resistant schizophrenia or schizo‐
affective disorder following a careful risk–benefit analysis and
collaborative discussion with the patient and families. The present
case offers some data to help understand the mechanisms of CIA;
although it is possible that there is not a common mechanism in
all such cases, on the basis of this successful re-challenge, the
suggestion that CIA is due to direct toxicity or an immune-mediated
mechanism appears to be less likely. At the patient level, this fourth
clozapine challenge represents an increase in quality of life for
J.B. whose medical therapeutic options were otherwise exhausted.
For future research directions, we propose that potential biomarkers
of clozapine immune response be prospectively assessed in new
clozapine starters. This would allow differentiation between those
who develop CIA and those with immune tolerance; the prediction
of those at risk of CIA; investigation of the relationship between
CIA and neutropenia and plasma clozapine concentrations; identi-
fication of enzymes responsible for the bioactivation of clozapine;
and phenotyping of peripheral leucocytes to identify cells which
precipitate neutropenia or which allow for the development of
immune tolerance.
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